SUPERNUS PHARMACEUTICALS, INC. Proceeds from Sale and Maturity of Marketable Securities
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Proceeds from Sale and Maturity of Marketable Securities of $173.19 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2022-11-09
- SUPERNUS PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2022-09-30 was $52.08M, a 24.20% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2022-06-30 was $92.19M, a 169.04% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2022-03-31 was $28.93M, a 41.65% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2021-09-30 was $68.70M, a 11.74% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2020 was $378.42M, a 49.47% increase from fiscal 2019.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2019 was $253.17M, a 217.15% increase from fiscal 2018.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2018 was $79.83M, a 178.56% increase from fiscal 2017.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2017 was $28.66M, a 9.95% decline from fiscal 2016.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2022-09-30 | $52.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $144.26M derived: sum of 2 quarters · filed 2022-11-09 | $173.19M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $92.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $121.11M 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | $28.93M 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | $68.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $102.97M derived: sum of 2 quarters · filed 2022-11-09 | $152.55M 10-Q · filed 2022-11-09 | $211.55M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $34.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $83.84M 10-Q · filed 2022-08-08 | $142.84M derived: sum of 3 quarters · filed 2022-08-08 | $204.33M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $49.58M 10-Q · filed 2022-05-12 | $108.58M derived: sum of 2 quarters · filed 2022-05-12 | $170.06M derived: sum of 3 quarters · filed 2022-05-12 | $374.64M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $59.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $120.49M derived: sum of 2 quarters · filed 2021-11-05 | $325.06M derived: sum of 3 quarters · filed 2021-11-05 | $378.42M 10-K · filed 2021-03-08 |
| 2020-09-30 | $61.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $266.06M derived: sum of 2 quarters · filed 2021-11-05 | $319.42M 10-Q · filed 2021-11-05 | $388.12M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $204.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $257.94M 10-Q · filed 2021-08-06 | $326.64M derived: sum of 3 quarters · filed 2021-08-06 | $414.94M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $53.36M 10-Q · filed 2021-05-07 | $122.06M derived: sum of 2 quarters · filed 2021-05-07 | $210.36M derived: sum of 3 quarters · filed 2021-05-07 | $259.38M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $68.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $157.00M derived: sum of 2 quarters · filed 2021-03-08 | $206.03M derived: sum of 3 quarters · filed 2021-03-08 | $253.17M 10-K · filed 2021-03-08 |
| 2019-09-30 | $88.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $137.32M derived: sum of 2 quarters · filed 2020-11-06 | $184.47M 10-Q · filed 2020-11-06 | $219.02M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-06-30 | $49.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | $96.17M 10-Q · filed 2020-08-17 | $130.72M derived: sum of 3 quarters · filed 2021-03-08 | $156.53M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-03-31 | $47.14M 10-Q · filed 2020-05-15 | $81.70M derived: sum of 2 quarters · filed 2021-03-08 | $107.50M derived: sum of 3 quarters · filed 2021-03-08 | $119.63M derived: sum of 4 quarters · filed 2021-03-08 |
| 2018-12-31 | $34.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $60.36M derived: sum of 2 quarters · filed 2021-03-08 | $72.48M derived: sum of 3 quarters · filed 2021-03-08 | $79.83M 10-K · filed 2021-03-08 |
| 2018-09-30 | $25.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $37.93M derived: sum of 2 quarters · filed 2019-11-08 | $45.27M 10-Q · filed 2019-11-08 | $50.88M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $12.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $19.47M 10-Q · filed 2019-08-09 | $25.07M derived: sum of 3 quarters · filed 2020-02-28 | $35.70M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $7.34M 10-Q · filed 2019-05-10 | $12.95M derived: sum of 2 quarters · filed 2020-02-28 | $23.58M derived: sum of 3 quarters · filed 2020-02-28 | $30.86M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $5.61M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $16.24M derived: sum of 2 quarters · filed 2020-02-28 | $23.52M derived: sum of 3 quarters · filed 2020-02-28 | $28.66M 10-K · filed 2020-02-28 |
| 2017-09-30 | $10.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $17.91M derived: sum of 2 quarters · filed 2018-11-09 | $23.05M 10-Q · filed 2018-11-09 | $32.48M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $7.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $12.42M 10-Q · filed 2018-08-09 | $21.84M derived: sum of 3 quarters · filed 2019-03-01 | $28.59M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $5.14M 10-Q · filed 2018-05-10 | $14.57M derived: sum of 2 quarters · filed 2019-03-01 | $21.31M derived: sum of 3 quarters · filed 2019-03-01 | $29.56M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $9.43M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $16.17M derived: sum of 2 quarters · filed 2019-03-01 | $24.42M derived: sum of 3 quarters · filed 2019-03-01 | $31.82M 10-K · filed 2019-03-01 |
| 2016-09-30 | $6.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $15.00M derived: sum of 2 quarters · filed 2017-11-09 | $22.40M 10-Q · filed 2017-11-09 | $26.31M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $8.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $15.66M 10-Q · filed 2017-08-03 | $19.57M derived: sum of 3 quarters · filed 2018-03-01 | $31.38M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $7.40M 10-Q · filed 2017-05-09 | $11.31M derived: sum of 2 quarters · filed 2018-03-01 | $23.12M derived: sum of 3 quarters · filed 2018-03-01 | $36.25M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $3.91M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $15.72M derived: sum of 2 quarters · filed 2018-03-01 | $28.85M derived: sum of 3 quarters · filed 2018-03-01 | $37.58M 10-K · filed 2018-03-01 |
| 2015-09-30 | $11.81M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-01-20 | $24.94M derived: sum of 2 quarters · filed 2017-01-23 | $33.67M 10-Q/A · filed 2017-01-20 | $45.16M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $13.13M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-01-23 | $21.86M 10-Q/A · filed 2017-01-23 | $33.35M derived: sum of 3 quarters · filed 2017-03-16 | $48.24M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | $8.73M 10-Q/A · filed 2017-01-20 | $20.22M derived: sum of 2 quarters · filed 2017-03-16 | $35.11M derived: sum of 3 quarters · filed 2017-03-16 | $53.11M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $11.49M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $26.38M derived: sum of 2 quarters · filed 2017-03-16 | $44.38M derived: sum of 3 quarters · filed 2017-03-16 | $53.47M 10-K · filed 2017-03-16 |
| 2014-09-30 | $14.89M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | $32.89M derived: sum of 2 quarters · filed 2017-01-20 | $41.99M 10-Q/A · filed 2017-01-20 | $70.13M derived: sum of 4 quarters · filed 2017-01-20 |
| 2014-06-30 | $18.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $27.09M 10-Q · filed 2015-08-07 | $55.23M derived: sum of 3 quarters · filed 2017-01-20 | $78.49M derived: sum of 4 quarters · filed 2017-01-20 |
| 2014-03-31 | $9.10M 10-Q · filed 2015-05-06 | $37.24M derived: sum of 2 quarters · filed 2017-01-20 | $60.49M derived: sum of 3 quarters · filed 2017-01-20 | $72.04M derived: sum of 4 quarters · filed 2017-01-20 |
| 2013-12-31 | $28.14M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | $51.39M derived: sum of 2 quarters · filed 2017-01-20 | $62.94M derived: sum of 3 quarters · filed 2017-01-20 | $75.81M 10-K/A · filed 2017-01-20 |
| 2013-09-30 | $23.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $34.80M derived: sum of 2 quarters · filed 2014-11-12 | $47.67M 10-Q · filed 2014-11-12 | $79.72M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $11.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $24.41M 10-Q · filed 2014-08-12 | $56.47M derived: sum of 3 quarters · filed 2015-03-12 | $66.21M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $12.87M 10-Q · filed 2014-05-13 | $44.92M derived: sum of 2 quarters · filed 2015-03-12 | $54.66M derived: sum of 3 quarters · filed 2015-03-12 | $62.04M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $32.05M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $41.79M derived: sum of 2 quarters · filed 2015-03-12 | $49.17M derived: sum of 3 quarters · filed 2015-03-12 | $49.47M 10-K · filed 2015-03-12 |
| 2012-09-30 | $9.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $17.12M derived: sum of 2 quarters · filed 2013-11-13 | $17.42M 10-Q · filed 2013-11-13 | $17.43M derived: sum of 4 quarters · filed 2014-03-21 |
| 2012-06-30 | $7.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $7.67M 10-Q · filed 2013-08-14 | $7.69M derived: sum of 3 quarters · filed 2014-03-21 | $18.11M derived: sum of 4 quarters · filed 2014-03-21 |
| 2012-03-31 | $293.00K 10-Q · filed 2013-05-15 | $308.00K derived: sum of 2 quarters · filed 2014-03-21 | $10.73M derived: sum of 3 quarters · filed 2014-03-21 | $18.81M derived: sum of 4 quarters · filed 2014-03-21 |
| 2011-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $10.44M derived: sum of 2 quarters · filed 2014-03-21 | $18.52M derived: sum of 3 quarters · filed 2014-03-21 | $26.87M 10-K · filed 2014-03-21 |
| 2011-09-30 | $10.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $18.51M derived: sum of 2 quarters · filed 2012-11-02 | $26.86M 10-Q · filed 2012-11-02 | |
| 2011-06-30 | $8.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | $16.43M 10-Q · filed 2012-08-13 | ||
| 2011-03-31 | $8.35M 10-Q · filed 2012-06-08 | |||
| 2010-12-31 | $58.90M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |